This is the first reactor barred in Japan under stricter safety protocols adopted after the Fukushima disaster.

Daiichi Sankyo Company (DSKYF – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

The nuclear fuel sample, the size of a grain of rice, was placed into a secure container Thursday, marking the end of the ...

Esperion Therapeutics' aggressive commercialization efforts have significantly boosted retail prescriptions and broadened ...

Japanese nuclear plant workers, for the first time, removed a small amount of melted fuel from one of the Fukushima Daiichi ...

A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...

Neurogene shares tumbled 35% last night after it disclosed that a pediatric patient with Rett syndrome experienced a severe ...

The growth report we've compiled suggests that Daiichi Sankyo Company's future prospects could be on the up.

Astra and partner Daiichi Sankyo Co Ltd said Tuesday a previously submitted ... are probing alleged illegal importation of ...

Bernstein analyst Miki Sogi maintained a Buy rating on Daiichi Sankyo Company (DSKYF – Research Report) yesterday and set a price target ...

Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong ...